natgillin/translations-raw huggingface dataset:
De mest almindelige bivirkninger, der forekom hos mindst 10 % af patienterne inkluderede: hovedpine, svimmelhed, insomni, hoste, dyspnø, orofaryngeale smerter, rinorré, kvalme, diarré, mavesmerter, førhøjede transaminaser, ekkymose, arthralgi, muskelspasmer, ekstremitetssmerter, træthed, febril neutropeni og pyreksi.
The most common adverse reactions occurring in at least 10% of patients included: headache, dizziness, insomnia, cough, dyspnoea, oropharyngeal pain, rhinorrhoea, nausea, diarrhoea, abdominal pain, transaminases increased, ecchymosis, arthralgia, muscle spasms, pain in extremity, fatigue, febrile neutropenia, and pyrexia.
De mest almindelige bivirkninger, der førte til seponering i løbet af de første 16 ugers behandling, var diarré (1,7 %) og kvalme (1,5 %).
The most common adverse reactions leading to discontinuation during the first 16 weeks of treatment were diarrhoea (1.7%), and nausea (1.5%).
De mest almindelige bivirkninger, som blev observeret med en højere hyppighed end ved placebo hos patienter med Lennox-Gastauts syndrom, var døsighed og opkastning.
The most common adverse reactions observed at a higher incidence than placebo in patients with Lennox-Gastaut syndrome were somnolence and vomiting.
De mest almindelige bivirkninger, som er observeret hos disse svin er feber, spisevægring og i alvorlige tilfælde manglende koordinering af bevægelser og trang til at ligge ned.
Most common adverse reactions observed in these pigs are pyrexia, anorexia and in severe cases ataxia and recumbency.
De mest almindelige bivirkninger, som forekom hos mindst 10 % af patienterne inkluderede: hovedpine, anæmi, nedsat appetit, insomni, hoste, kvalme, diarré, alopeci, pruritus, myalgi, pyreksi, træthed, influenzalignende symptomer, asteni, kulderystelser og perifert ødem.
The most common adverse reactions occurring in at least 10% of patients included: headache, anaemia, decreased appetite, insomnia, cough, nausea, diarrhoea, alopecia, pruritus, myalgia, pyrexia, fatigue, influenza- like illness, asthenia, chills and peripheral oedema.
De mest almindelige bivirkninger, som forekom hos mindst 10 % af patienterne inkluderede: hovedpine, anæmi, nedsat appetit, insomni, hoste, kvalme, diarré, alopeci, pruritus, myalgi, pyreksi, træthed, influenzalignende symptomer, asteni, kulderystelser og perifert ødem.
The most common adverse reactions occurring in at least 10% of patients included: headache, anaemia, decreased appetite, insomnia, cough, nausea, diarrhoea, alopecia, pruritus, myalgia, pyrexia, fatigue, influenza-like illness, asthenia, chills and peripheral oedema.
De mest almindelige bivirkninger, som medførte seponering i rufinamid-behandlingsgruppen var udslæt og opkastning.
The most common adverse reactions resulting in discontinuation from the rufinamide treatment group were rash and vomiting.
De mest almindelige bivirkninger, som medførte seponering i rufinamid-behandlingsgruppen, var udslæt og opkastning.
The most common adverse reactions resulting in discontinuation from the Rufinamide treatment group were rash and vomiting.
De mest almindelige indberettede bivirkninger, der blev observeret i kliniske forsøg, omfatter svimmelhed, hovedpine, blødning, kvalme, blødning på venepunkturstedet, blødning efter indgrebet og sårsekretion.
The most commonly reported adverse reactions observed in clinical trials are dizziness, headache, haemorrhage, nausea, venipuncture site haemorrhage, post procedural haemorrhage and wound secretion.
De mest almindelige individuelle bivirkninger, der optræder hos over 10 % af patienterne, er diarré, udslæt, pruritus (kløe), træthed, kvalme, opkastning, nedsat appetit og mavesmerter.
The most common individual side effects, affecting more than 10% of patients, are diarrhoea, rash, pruritus (itching), fatigue (tiredness), nausea (feeling sick), vomiting, decreased appetite and abdominal pain (stomach ache).
De mest almindelige komorbiditeter var hypertension (56,8%) og strukturel hjertesygdom (41,5%) inklusive koronar hjertesygdom. (21,8%).
The most common co-morbidities were hypertension (56.8%) and structural heart disease (41.5%) including coronary heart disease (21.8%).
De mest almindelige rapporterede (≥ 10 %) lægemiddelrelaterede bivirkninger var i begge patientgrupper: let kvalme, opkastning, diarré, abdominalsmerter, træthed, myalgi og muskelkramper samt udslæt.
The most commonly reported (≥ 10%) medicinal product-related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
De mest almindelige rapporterede (10 %) behandlingsrelaterede bivirkninger var: let kvalme, opkastning, diarré, abdominalsmerter, træthed, myalgi og muskelkramper samt udslæt.
The most commonly reported (≥ 10 %) treatment-related adverse reactions were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
De mest almindelige rapporterede (10%) lægemiddelrelaterede bivirkninger var i begge patientgrupper: let kvalme, opkastning, diarré, abdominalsmerter, træthed, myalgi og muskelkramper samt udslæt.
The most commonly reported ( 10%) drug- related adverse reactions in both settings were mild nausea, vomiting, diarrhoea, abdominal pain, fatigue, myalgia, muscle cramps and rash.
De mest almindelige rapporterede bivirkninger er reaktioner på injektionsstedet (som smerte, hævelse. kløe, rødme og blødning på indstiksstedet), infektioner (som infektioner i de øvre luftveje, bronkitis, blæreinfektioner og hudinfektioner), allergiske reaktioner, udvikling af autoantistoffer, kløe og feber.
The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, bronchitis, bladder infections and skin infections), allergic reactions, development of autoantibodies, itching, and fever.
De mest almindelige rapporterede bivirkninger hos patienter i behandling med Cymbalta var kvalme, hovedpine, mundtørhed, søvnighed og svimmelhed.
The most commonly reported adverse reactions in patients treated with Cymbalta were nausea, headache, dry mouth, somnolence, and dizziness.
De mest almindelige rapporterede bivirkninger hos patienter i behandling med Duloxetin Lilly var kvalme, hovedpine, mundtørhed, søvnighed og svimmelhed.
The most commonly reported adverse reactions in patients treated with Duloxetine Lilly were nausea, headache, dry mouth, somnolence, and dizziness.
De mest almindelige rapporterede og/eller klinisk relevante behandlingsrelaterede bivirkninger var gastrointestinale symptomer (specielt diarré, kvalme, opkastning, mavesmerter og stomatitis), hånd- og fodsyndrom (palmo-plantar erytrodysæstesi), træthed, asteni, anoreksi, kardiotoksicitet, øget renal dysfunktion hos dem med præeksisterende kompromitteret nyrefunktion samt trombose/embolisme.
The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/embolism.
De mest almindelige rapporterede og/eller klinisk relevante behandlingsrelaterede bivirkninger var gastrointestinale symptomer (specielt diarré, kvalme, opkastning, mavesmerter og stomatitis), hånd- og fodsyndrom (palmoplantar erytrodysæstesi), træthed, asteni, anoreksi, kardiotoksicitet, øget renal dysfunktion hos dem med præeksisterende kompromitteret nyrefunktion samt trombose/embolisme.
The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with preexisting compromised renal function, and thrombosis/embolism.
De mest almindelige symptomer er milde influenza-lignende symptomer som hovedpine eller feber, udpræget træthed, mørkfarvet urin, lys afføring, gulfarvning af hud eller øjne (gulsot).
The main signs of the illness include mild signs of flu such as headache or fever, feeling very tired, dark urine, pale stools (faeces), yellow skin or eyes (jaundice).
De mest almindelige årsager til uegnethed til VKA-behandling i AVERROES studiet omfattede: ude af stand til/vil sandsynligvis ikke kunne opnå INR’er med nødvendige intervaller (42,6%), patient afslog behandling med VKA (37,4%), CHADS2 score = 1 og lægen frarådede VKA (21,3%), patient vil muligvis ikke være i stand til at følge patientvejledningen for VKA-lægemidler (15,0%) og problemer/forventede problemer med at komme i kontakt med patienten i tilfælde af akut dosisændring (11,7%).
Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), and difficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%).
De mest almindeligt (≥ 5 %) rapporterede bivirkninger hos patienter med andre indikationer, behandlet med pramipexol var: kvalme, hovedpine, svimmelhed og træthed.
The most commonly (≥ 5 %) reported adverse drug reactions in patients with another indication treated with pramipexole were nausea, headache, dizziness and fatigue.
De mest almindeligt (≥ 5 %) rapporterede bivirkninger hos patienter med Parkinsons sygdom, som oftere ses efter behandling med pramipexol end efter behandling med placebo er kvalme, dyskinesi, hypotension, svimmelhed, somnolens, søvnløshed, forstoppelse, hallucinationer, hovedpine og træthed.
The most commonly (≥ 5 %) reported adverse drug reactions in patients with Parkinson’s disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
De mest almindeligt (≥ 5%) rapporterede bivirkninger hos patienter med andre indikationer, behandlet med pramipexol var: kvalme, hovedpine, svimmelhed og træthed.
The most commonly (≥ 5%) reported adverse drug reactions in patients with other indication treated with pramipexole were nausea, headache, dizziness and fatigue.
De mest almindeligt ( 5%) rapportede bivirkninger hos patienter med Parkinsons sygdom, som oftere ses efter behandling med pramipexol end efter behandling med placebo er kvalme, dyskinesi, hypotension, svimmelhed, døsighed, søvnløshed, forstoppelse, hallucinationer, hovedpine og træthed.
The most commonly (≥ 5%) reported adverse drug reactions in patients with Parkinson’s disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
De mest almindeligt ( 5%) rapportede bivirkninger hos patienter med Parkinsons sygdom, som oftere ses efter behandling med pramipexol end efter behandling med placebo er kvalme, dyskinesi, hypotension, svimmelhed, døsighed, søvnløshed, forstoppelse, hallucinationer, hovedpine og træthed.
The most commonly (≥5%) reported adverse reactions in patients with Parkinson’s disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
De mest almindeligt ( 5%) rapporterede bivirkninger hos patienter med restless legs syndrom, er kvalme, hovedpine, svimmelhed og træthed.
The most commonly (≥ 5%) reported adverse drug reactions in patients with Restless Legs Syndrome treated with pramipexole were nausea, headache, dizziness and fatigue.
De mest almindeligt forekommende (≥ 10 %) bivirkninger i alle grader var anæmi (97,3 %), leukopeni (95,6 %), neutropeni (93,5 %), trombocytopeni (47,4 %) og diarré (46,6 %).
The most commonly (≥10%) occurring adverse reactions in all grades were anaemia (97.3%), leukopenia (95.7%), neutropenia (93.5%), thrombocytopenia (47.4%), and diarrhoea (46.6%).
De mest almindeligt forekommende (≥ 5 %) grad ≥3 bivirkninger i cabazitaxel-gruppen var neutropeni (81,7 %), leukopeni (68,2 %), anæmi (10,5 %), febril neutropeni (7,5 %), diarré 6,2 %).
The most commonly (≥5%) occurring grade ≥3 adverse reactions in the cabazitaxel group were neutropenia (81.7%), leukopenia (68.2%), anaemia (10.5%), febrile neutropenia (7.5%), diarrhoea (6.2%).
De mest almindeligt indberettede invasive svampeinfektioner var forårsaget af Candida, Pneumocystis, Aspergillus og Histoplasma).
The most commonly reported invasive fungal infections included Candida, Pneumocystis, Aspergillus, and Histoplasma.
De mest almindeligt observerede bivirkninger relateret til anvendelsen af Tasmar, som forekommer hyppigere end hos placebobehandlede patienter fremgår af nedenstående tabel.
The most commonly observed adverse reaction associated with the use of Tasmar, occurring more frequently than in placebo-treated patients are listed in the table below.
De mest almindeligt rapporterede bivirkninger (≥ 20%) blandt patienter, der blev behandlet med begge belatacept-baserede regimer (MI og LI) op til år 3, er diarre, anæmi, urinvejsinfektion, perifere ødemer, forstoppelse, hypertension, pyreksi, kvalme, transplantatdysfunktion, hoste, opkastning, leukopeni, hypofosfatæmi og hovedpine.
The most commonly reported adverse reactions (≥ 20%) among patients treated with both belatacept- based regimens (MI and LI) up to Year 3 are diarrhoea, anaemia, urinary tract infection, peripheral oedema, constipation, hypertension, pyrexia, nausea, graft dysfunction, cough, vomiting, leukopenia, hypophosphataemia, and headache.
De mest almindeligt rapporterede bivirkninger i fase III kliniske studier har være mave-tarm- sygdomme, herunder diarré (15,7 %) og kvalme (13,9 %).
The most commonly reported adverse reactions in Phase III clinical studies have been gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%).
De mest almindeligt rapporterede bivirkninger i kliniske studier var inden for blod og lymfesystem, herunder anæmi (45,7 %), neutropeni (45,3 %) og trombocytopeni (27 %), inden for almene symptomer og reaktioner på administrationsstedet, herunder træthed (28,3 %), pyreksi (21 %) og perifert ødem (13 %), samt inden for infektioner og parasitære sygdomme, herunder pneumoni (10,7 %).
The most commonly reported adverse reactions in clinical studies have been blood and lymphatic system disorders including anaemia (45.7%), neutropenia (45.3%) and thrombocytopenia (27%); in general disorders and administration site conditions including fatigue (28.3%), pyrexia (21%) and oedema peripheral (13%); and in infections and infestations including pneumonia (10.7%).
De mest almindeligt rapporterede bivirkninger med docetaxel alene var: Neutropeni (som var reversibel og ikke kumulativ, median-dage til nadir var 7 dage og median-varigheden af alvorlig neutropeni (< 500 celler/mm3) var 7 dage), anæmi, alopeci, kvalme, opkastning, stomatitis, diarré og asteni.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
De mest almindeligt rapporterede bivirkninger med docetaxel alene var: neutropeni (som var reversibel og ikke kumulativ, median-dagen til nadir var 7 dage og median-varigheden af alvorlig neutropeni (< 500 celler/mm3) var 7 dage), anæmi, alopeci, kvalme, opkastning, stomatitis, diarré og asteni.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (< 500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
De mest almindeligt rapporterede bivirkninger med docetaxel var: neutropeni (som var reversibel og ikke kumulativ, median-dagen til nadir var 7 dage og median-varigheden af alvorlig neutropeni (< 500 celler/mm3) var 7 dage), anæmi, alopeci, kvalme, opkastning, stomatitis, diarré og asteni.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
De mest almindeligt rapporterede bivirkninger var hovedpine, svimmelhed, træthed og døsighed.
The most commonly reported adverse reactions overall were headache, dizziness, fatigue, and somnolence.
De mest almindeligt rapporterede bivirkninger ved lacosamidbehandling var svimmelhed, hovedpine, kvalme og diplopi (dobbeltsyn).
The most frequently reported adverse reactions with lacosamide treatment were dizziness, headache, nausea and diplopia.
De mest almindeligt rapporterede bivirkninger ved tacrolimus (der forekommer hos >10 % af patienter) tremor, nedsat nyrefunktion, hyperglykæmiske tilstande, diabetes mellitus, hyperkaliæmi, infektioner, hypertension og insomnia.
The most commonly reported adverse reactions for tacrolimus (occurring in >10% of patients) are tremor, renal impairment, hyperglycaemic conditions, diabetes mellitus, hyperkalaemia, infections, hypertension and insomnia.
De mest almindeligt rapporterede reaktioner var hyperglykæmi, hypokaliæmi, neutropeni og øget alanin-aminotransferase (ALAT).
The most commonly reported reactions were hyperglycaemia, hypokalaemia, neutropenia, and increased alanine amino transferase (ALT).
De mest almindeligt sete bivirkninger, der opstod under behandlingen, var kvalme (13 %), diarré (18 %) og hovedpine (13 %).
The most commonly seen treatment emergent adverse reactions were nausea (13%), diarrhoea (18%) and headache (13%).
De mest alvorlige bivirkninger er gastrointestinale perforationer (huller i tarmen), hæmorrhagi (blødning) og arteriel tromboemboli (blodpropper i arterierne).
The most serious side effects are gastrointestinal perforation (hole in the gut), haemorrhage (bleeding) and arterial thromboembolism (blood clots in the arteries).
De mest alvorlige bivirkninger er infektioner, makulaødem (hævelse af makula, den centrale del af nethinden bagest i øjet) og forbigående atrioventrikulær blok (en form for forstyrrelse af hjerterytmen) ved behandlingens start.
The most serious side effects are infections, macular oedema (swelling in the macula, the central part of the retina at the back of the eye) and transient atrioventricular block (a type of heart rhythm disorder) at the start of treatment.
De mest alvorlige bivirkninger forbundet med behandling med ramucirumab (som enkeltstof eller i kombination med cytotoksisk kemoterapi) var følgende:
The most serious adverse reactions associated with ramucirumab treatment (as a single agent or in combination with cytotoxic chemotherapy) were:
De mest alvorlige bivirkninger hos patienter, der fik Xofigo, er
The most serious side effects in patients receiving Xofigo are
De mest alvorlige bivirkninger opstår som ikke almindelige til sjældne, og omfatter kardiovaskulære hændelser som f.eks. myokardieinfarkt og alvorlig hypotension, og overfølsomhedsreaktioner som f.eks. anafylaksi, angioødem og alvorlige hud- reaktioner.
The most serious reactions occur uncommonly to rarely, and include cardiovascular events such as myocardial infarction and severe hypotension, as well as hypersensitivity events such as anaphylaxis, angioedema and severe skin reactions.
De mest alvorlige bivirkninger var svære allergiske reaktioner (ikke- almindelig - kan påvirke op til 1 ud af 100 personer) og lette til moderate opkastninger (meget almindelig - kan påvirke mere end 1 ud af 10 personer).
The most serious side effects were severe allergic reactions (seen uncommonly – may affect up to 1 in 100 people) and mild to moderate vomiting (seen very commonly – may affect more than 1 in 10 people).
De mest alvorlige bivirkninger, der er blevet observeret med Torisel i kliniske forsøg, er allergiske reaktioner/reaktioner ved infusionen (herunder nogle livstruende og sjældne, letale reaktioner), hyperglykæmi/glucoseintolerans, infektioner, interstitiel lungesygdom (pneumoni), hyperlipæmi, intrakranial blødning, nyreinsufficiens, perforering af tarm, komplikationer ved sårheling, trombocytopeni, neutropeni (herunder febril neutropeni), lungeemboli.
The most serious reactions observed with Torisel in clinical trials are hypersensitivity/infusion reactions (including some life-threatening and rare fatal reactions), hyperglycaemia/glucose intolerance, infections, interstitial lung disease (pneumonitis), hyperlipaemia, intracranial haemorrhage, renal failure, intestinal perforation, wound healing complication, thrombocytopenia, neutropenia (including febrile neutropenia), pulmonary embolism.
De mest alvorlige bivirkninger, der hyppigere blev observeret med lenalidomid/dexamethason end med placebo/dexamethason-kombinationen, var:
The most serious adverse reactions observed more frequently in lenalidomide/dexamethasone than placebo/dexamethasone combination were:
De mest alvorlige bivirkninger, der kan opstå i forbindelse med behandling med blinatumomab, inkluderer: infektioner (31,7 %), neurologiske hændelser (16,4 %), neutropeni/febril neutropeni (15,3 %), cytokinfrigivelsessyndrom (0,5 %) og tumorlysesyndrom (0,5 %).
The most serious adverse reactions that may occur during blinatumomab treatment include: infections (31.7%), neurologic events (16.4%), neutropenia/febrile neutropenia (15.3%), cytokine release syndrome (0.5%), and tumour lysis syndrome (0.5%).
De mest fremtrædende bivirkninger, der er rapporteret i forbindelse med Stocrin i kombination med andre anti-hiv-lægemidler, er udslæt og symptomer fra nervesystemet.
The most notable unwanted effects reported with Stocrin in combination with other anti-HIV medicines are skin rash and nervous system symptoms.
De mest fremtrædende bivirkninger, der er rapporteret i forbindelse med SUSTIVA i kombination med andre anti-hiv-lægemidler, er udslæt og symptomer fra nervesystemet.
The most notable unwanted effects reported with SUSTIVA in combination with other anti-HIV medicines are skin rash and nervous system symptoms.
De mest fremtrædende symptomer på IBS-D er:
The main symptoms of IBS-D include:
De mest hensigtmæssige strategier til at monitorere off-label-brug inden for nationale grænser
The most appropriate strategies to monitor the off label use within national territories
De mest hyppige bivirkninger (optræder hos mere en 1 ud af hver 5 behandlede), når Mekinist tages i kombination med dabrafenib, er feber, træthed, kvalme, hovedpine, kulderystelser, diarré, udslæt, ledsmerter, højt blodtryk, opkastninger og hoste.
When Mekinist is taken in combination with dabrafenib the most common side effects (seen more than 1 in 5 people) are fever, tiredness, nausea, headache, chills, diarrhea, rash, joint pain, high blood pressure, vomiting and cough.
De mest hyppigt indberettede lægemiddelbivirkninger er diarré, udslæt, kvalme, hypertension og hovedpine.
The most commonly reported adverse drug reactions have been diarrhoea, rash, nausea, hypertension, and headache.
De mest hyppigt rapporterede bivirkninger var lysfølsomhedsreaktioner (69%), øsofagusstenose (40%), opkastning (32%), brystsmerter af ikke- kardial oprindelse (20%), pyreksi (20%), dysfagi (19%), obstipation (13%), dehydrering (12%) og kvalme (11%).
The most frequently reported adverse reactions were photosensitivity reactions (69%), oesophageal stenosis (40%), vomiting (32%), chest pain of non-cardiac origin (20%), pyrexia (20%), dysphagia (19%), constipation (13%), dehydration (12%) and nausea (11%).
De mest hyppigt rapporterede bivirkningsreaktioner var reaktioner på applikationsstedet hos 23,1 % af patienterne.
The most commonly reported adverse drug reactions were application site reactions, occurring in 23.1% of patients.